India, Sept. 26 -- Calidi Biotherapeutics Inc. (CLDI), a biotechnology company, on Friday announced receiving a notice of non-compliance from the New York Stock Exchange (NYSE) American LLC regarding a deficiency in the company's stockholder equity. The notice was issued on September 21, 2026, and highlighted a violation of listing standards Part A, section 1003(a)(ii), which requires a trading company to have at least $4 million in stockholders' equity if a net loss was reported in the last three of four fiscal years. NYSE also noted that Calidi was not eligible for any exemptions to the rule. The company is now expected to file a plan by October 21, 2026, to NYSE American detailing the steps it intends to take to regain compliance. During...